Cardiovascular Drugs — MCQs

Cardiovascular Drugs Indian Medical PG Practice Questions and MCQs

Question 861: Which of the following statements is NOT true regarding the use of beta-blockers in Congestive Heart Failure?

A. Beta-blockers should be started at a very low dose and slowly titrated upwards.
B. Carvedilol is a widely used beta-blocker in CHF.
C. Beta-blockers are the drug of choice in acute decompensated heart failure. (Correct Answer)
D. Beta-blockers can reduce mortality in CHF patients.

Explanation: **Explanation:** The correct answer is **C**. Beta-blockers are **contraindicated** in acute decompensated heart failure (ADHF) because they possess negative inotropic effects. In an acute state, the heart relies on sympathetic drive to maintain cardiac output; blocking these receptors can further depress myocardial contractility, worsening pulmonary edema and cardiogenic shock. They should only be initiated once the patient is stable and "dry" (euvolemic). **Analysis of other options:** * **Option A:** This is a true statement. Beta-blockers must be started at **"low dose and slow titration"** (the "start low, go slow" approach) to prevent an acute drop in ejection fraction as the heart adapts to the decreased sympathetic tone. * **Option B:** Carvedilol is a non-selective beta-blocker with additional **alpha-1 blocking** and antioxidant properties, making it a cornerstone therapy in chronic heart failure. * **Option C:** As explained, beta-blockers reduce the remodeling of the heart caused by chronic catecholamine exposure, significantly **reducing mortality** and hospitalization in patients with HFrEF (Heart Failure with reduced Ejection Fraction). **High-Yield Clinical Pearls for NEET-PG:** * **The "Big Three":** Only three beta-blockers are proven to reduce mortality in CHF: **Bisoprolol, Carvedilol, and Metoprolol succinate** (long-acting). * **Mechanism:** They work by blocking the "vicious cycle" of sympathetic overactivation, reducing heart rate (increasing diastolic filling time), and inhibiting renin release. * **Contraindications:** Avoid in ADHF, symptomatic bradycardia, and severe reactive airway disease (asthma).

Question 862: All of the following are vasodilators except?

A. Methyldopa (Correct Answer)
B. Nitroprusside
C. Hydralazine
D. Diazoxide

Explanation: **Explanation:** The core concept here is distinguishing between **direct-acting vasodilators** and **centrally acting sympatholytics**. **1. Why Methyldopa is the correct answer:** Methyldopa is **not** a vasodilator. It is a **centrally acting alpha-2 adrenergic agonist**. It acts as a prodrug, converted into alpha-methylnorepinephrine in the brain, which stimulates central $\alpha_2$ receptors. This reduces sympathetic outflow from the vasomotor center, leading to a decrease in peripheral vascular resistance and heart rate. While the end result is a drop in blood pressure, the mechanism is neurogenic, not a direct action on the vessel walls. **2. Analysis of incorrect options (Direct Vasodilators):** * **Nitroprusside:** A potent parenteral vasodilator that releases **Nitric Oxide (NO)**. it acts on both arterioles and venules (balanced vasodilator) to reduce both preload and afterload. * **Hydralazine:** A direct **arteriolar vasodilator** (minimal effect on veins). It acts by increasing cGMP levels and interfering with calcium release in smooth muscle. * **Diazoxide:** A potent **K+ channel opener** that hyperpolarizes vascular smooth muscle cells, leading to rapid arteriolar vasodilation. It is chemically related to thiazide diuretics but lacks diuretic activity. **High-Yield Clinical Pearls for NEET-PG:** * **Methyldopa** is the traditional drug of choice for **hypertension in pregnancy** (safe for the fetus). * **Side effect of Methyldopa:** Positive Coombs test (autoimmune hemolytic anemia) and hyperprolactinemia. * **Hydralazine** is associated with **Drug-Induced Lupus Erythematosus (DILE)**, especially in slow acetylators. * **Diazoxide** can cause **hyperglycemia** (inhibits insulin release), making it useful in treating insulinomas. * **Nitroprusside toxicity:** Prolonged infusion can lead to **Cyanide/Thiocyanate toxicity** (treated with Sodium Thiosulfate).

Question 863: Postural hypotension is the common side effect of which of the following?

A. ACE inhibitors
B. Alpha receptor blockers (Correct Answer)
C. Selective beta1 blockers
D. Arteriolar dilators

Explanation: **Explanation:** **Why Alpha Receptor Blockers are the Correct Answer:** Postural (orthostatic) hypotension is a hallmark side effect of **Alpha-1 receptor blockers** (e.g., Prazosin, Terazosin, Doxazosin). Under normal physiological conditions, standing up causes venous pooling in the lower limbs; the body compensates via the baroreceptor reflex, which triggers sympathetic-mediated vasoconstriction through alpha-1 receptors on veins and arterioles. Alpha-blockers inhibit this compensatory vasoconstriction, leading to a sudden drop in blood pressure upon standing. This is most severe with the first dose, a phenomenon known as the **"First-dose effect."** **Analysis of Incorrect Options:** * **ACE Inhibitors:** While they can cause hypotension, it is rarely postural. Their most characteristic side effects are dry cough (due to bradykinin accumulation), hyperkalemia, and angioedema. * **Selective Beta-1 Blockers:** These primarily act on the heart to decrease heart rate and contractility. They do not significantly interfere with the peripheral vascular tone required to prevent postural drops. * **Arteriolar Dilators (e.g., Hydralazine):** These drugs primarily cause reflex tachycardia and fluid retention. Because they do not affect the venous side (capacitance vessels) as significantly as alpha-blockers, postural hypotension is less common. **High-Yield Clinical Pearls for NEET-PG:** * **First-Dose Phenomenon:** To minimize syncope, alpha-blockers should be started at a low dose and administered at **bedtime**. * **Uroselevtivity:** Tamsulosin (Alpha-1A blocker) is used for BPH and has a lower incidence of postural hypotension compared to non-selective alpha-1 blockers. * **Other drugs causing postural hypotension:** Diuretics (volume depletion), TCAs, and Nitrates.

Question 864: Which calcium channel blocker has the maximum effect on conduction in the heart?

A. Phenylamine
B. Nifedipine
C. Diltiazem
D. Verapamil (Correct Answer)

Explanation: **Explanation:** Calcium Channel Blockers (CCBs) are classified into two main categories: **Dihydropyridines (DHPs)** and **Non-Dihydropyridines**. The difference in their clinical effect depends on their binding affinity for calcium channels in the vascular smooth muscle versus the myocardium. **Why Verapamil is Correct:** Verapamil belongs to the **Phenylalkylamine** class. It has the highest selectivity for the myocardium and the cardiac conduction system (SA and AV nodes). By blocking L-type calcium channels during Phase 0 of the action potential in nodal tissues, it significantly slows the rate of recovery of the channel. This leads to a profound **negative dromotropic effect** (decreased conduction velocity) and **negative chronotropic effect** (decreased heart rate). Therefore, it is the drug of choice among CCBs for supraventricular tachycardias. **Analysis of Incorrect Options:** * **Phenylamine (Option A):** This is likely a distractor or a misspelling of Prenylamine (an obsolete CCB). It is not a standard first-line agent for conduction issues. * **Nifedipine (Option B):** A Dihydropyridine that acts primarily on **vascular smooth muscle** (potent vasodilator). It has minimal direct effect on cardiac conduction at clinical doses and may actually cause reflex tachycardia. * **Diltiazem (Option C):** A Benzothiazepine that occupies a middle ground. While it does affect conduction, its potency on the AV node is significantly **less than Verapamil** but greater than Nifedipine. **High-Yield NEET-PG Pearls:** * **Order of Cardiac Depressant Effect:** Verapamil > Diltiazem > Nifedipine. * **Order of Vasodilatory Potency:** Nifedipine > Diltiazem > Verapamil. * **Clinical Contraindication:** Never combine Verapamil with **Beta-blockers** intravenously, as it can lead to severe bradycardia or complete heart block. * **Side Effect:** Verapamil is notorious for causing **constipation** (due to block of calcium channels in GI smooth muscle) and gingival hyperplasia.

Question 865: Which of the following is the shortest acting beta-blocker?

A. Acebutolol
B. Sotalol
C. Bisoprolol
D. Esmolol (Correct Answer)

Explanation: ### Explanation **Correct Answer: D. Esmolol** **Why Esmolol is the correct answer:** Esmolol is a **cardioselective (β1)** antagonist characterized by its ultra-short duration of action. The underlying pharmacological reason is its metabolism: Esmolol contains an **ester linkage** that is rapidly hydrolyzed by **red blood cell esterases**. * **Onset of action:** 2–5 minutes. * **Elimination half-life:** Approximately **9 minutes**. This makes it ideal for "titratable" intravenous use in acute settings where rapid reversal of beta-blockade might be necessary if adverse effects occur. **Why the other options are incorrect:** * **A. Acebutolol:** A cardioselective beta-blocker with **Intrinsic Sympathomimetic Activity (ISA)**. It has a half-life of about 3–4 hours. * **B. Sotalol:** A non-selective beta-blocker that also possesses **Class III antiarrhythmic** properties (potassium channel blockade). It has a long half-life of 12 hours and is excreted unchanged by the kidneys. * **C. Bisoprolol:** A highly cardioselective beta-blocker used primarily in chronic heart failure and hypertension. It has a half-life of 9–12 hours, allowing for once-daily dosing. **High-Yield Clinical Pearls for NEET-PG:** * **Indications for Esmolol:** Supraventricular tachycardia (SVT), intraoperative hypertension, and aortic dissection (to reduce shear stress). * **Metabolism Fact:** Because it is metabolized by RBC esterases, its clearance is independent of renal or hepatic function. * **Longest acting beta-blocker:** **Nadolol** (half-life ~20–24 hours). * **Beta-blocker with Nitric Oxide (NO) activity:** **Nebivolol** (most cardioselective) and **Carvedilol**. * **Lipid solubility:** Propranolol is highly lipid-soluble (crosses BBB), whereas Atenolol is water-soluble (low CNS side effects).

Question 866: Which of the following conditions does NOT contribute to Digoxin toxicity?

A. Hyperkalemia (Correct Answer)
B. Hypercalcemia
C. Renal failure
D. Hypomagnesemia

Explanation: **Explanation:** The correct answer is **Hyperkalemia**. Digoxin toxicity is primarily influenced by electrolyte imbalances and impaired clearance. **1. Why Hyperkalemia is the correct answer:** Digoxin works by inhibiting the **Na⁺/K⁺-ATPase pump** [3] by competing with Potassium (K⁺) for the same binding site on the extracellular surface. * In **Hypokalemia**, there is less competition for the pump, allowing more Digoxin to bind, which precipitates toxicity [4]. * Conversely, **Hyperkalemia** reduces Digoxin binding to the pump, thereby antagonizing its effects [5]. Interestingly, while hypokalemia *predisposes* to toxicity, hyperkalemia is often a *consequence* of acute severe digoxin poisoning (due to total pump inhibition). **2. Why the other options are incorrect:** * **Hypercalcemia:** Digoxin increases intracellular Calcium [2]. Elevated serum Calcium acts synergistically with Digoxin, increasing the risk of cardiac arrhythmias (the "Stone Heart" phenomenon). * **Renal Failure:** Digoxin is primarily excreted unchanged by the kidneys. A decrease in Glomerular Filtration Rate (GFR) leads to drug accumulation and toxicity. * **Hypomagnesemia:** Magnesium is a cofactor for the Na⁺/K⁺-ATPase pump. Low levels sensitize the myocardium to Digoxin-induced arrhythmias. **High-Yield Clinical Pearls for NEET-PG:** * **Most common arrhythmia:** Ventricular Bigeminy. * **Most characteristic arrhythmia:** Paroxysmal Atrial Tachycardia with AV block. * **Visual disturbance:** Xanthopsia (yellow-green halos around lights). * **Antidote:** Digoxin-specific Fab fragments (Digibind). * **Drugs increasing Digoxin levels:** Quinidine, Verapamil, and Amiodarone (by displacing it from tissue binding sites and reducing renal clearance) [1].

Question 867: Which of the following drugs should not be used empirically in an elderly patient with severe hypertension?

A. Enalapril
B. Amlodipine
C. Chlorthalidone
D. Prazosin (Correct Answer)

Explanation: **Explanation:** The correct answer is **Prazosin**. **Why Prazosin is the correct choice:** Prazosin is a selective **alpha-1 blocker**. Its use as an empirical, first-line monotherapy for hypertension is discouraged, especially in the elderly, due to the **"First-Dose Phenomenon."** This refers to sudden, severe orthostatic hypotension and syncope occurring shortly after the initial dose. In elderly patients, who often have impaired baroreceptor reflexes and are at a higher risk of falls and fractures, this side effect can be catastrophic. Furthermore, the ALLHAT trial demonstrated that alpha-blockers are less effective than other classes in preventing heart failure. **Why the other options are incorrect:** * **Enalapril (ACE Inhibitor):** These are standard first-line agents, particularly beneficial in patients with comorbid diabetes or chronic kidney disease (CKD). * **Amlodipine (Calcium Channel Blocker):** CCBs are highly effective and recommended as first-line therapy for elderly patients and those of African descent with isolated systolic hypertension. * **Chlorthalidone (Thiazide-like Diuretic):** Thiazides/Thiazide-like diuretics are preferred first-line agents for elderly patients. Chlorthalidone is often favored over hydrochlorothiazide due to its longer half-life and superior evidence in reducing cardiovascular events. **High-Yield Clinical Pearls for NEET-PG:** * **Beers Criteria:** Prazosin is listed in the Beers Criteria as a potentially inappropriate medication for the elderly due to the high risk of orthostatic hypotension. * **Indication for Prazosin:** It is primarily used as an add-on therapy for resistant hypertension or for symptomatic relief in **Benign Prostatic Hyperplasia (BPH)**. * **Management:** To minimize the first-dose effect, the drug should be started at a low dose and administered at **bedtime**.

Question 868: Which of the following drugs is contraindicated in variant angina?

A. Diltiazem
B. Nitrates
C. Propranolol (Correct Answer)
D. Verapamil

Explanation: **Explanation:** The correct answer is **Propranolol**. **1. Why Propranolol is Contraindicated:** Variant angina (Prinzmetal angina) is caused by **coronary artery vasospasm** rather than fixed atherosclerotic obstruction. Propranolol is a non-selective beta-blocker. By blocking $\beta_2$ receptors on coronary blood vessels, it leaves the **$\alpha_1$-adrenergic receptors unopposed**. When circulating catecholamines stimulate these unopposed $\alpha_1$ receptors, it leads to further vasoconstriction and worsening of the coronary spasm, potentially precipitating a myocardial infarction. **2. Why the Other Options are Incorrect:** * **Diltiazem & Verapamil (Options A & D):** These are Calcium Channel Blockers (CCBs). CCBs are the **drugs of choice** for variant angina because they cause direct coronary vasodilation and prevent the calcium-mediated contraction of vascular smooth muscle. * **Nitrates (Option B):** Nitrates are effective in variant angina because they are potent vasodilators. They convert to nitric oxide, increasing cGMP levels, which leads to the relaxation of coronary arteries and relief of the spasm. **3. NEET-PG High-Yield Pearls:** * **Drug of Choice for Acute Attack:** Sublingual Nitroglycerin. * **Prophylactic Drug of Choice:** Calcium Channel Blockers (e.g., Diltiazem, Verapamil, or Amlodipine). * **Avoid in Variant Angina:** Non-selective beta-blockers (Propranolol) and selective $\beta_1$ blockers (Atenolol/Metoprolol) should generally be avoided as they can still lead to unopposed $\alpha$ activity. * **Cocaine-induced Vasospasm:** Similar to variant angina, beta-blockers are strictly contraindicated in cocaine-induced chest pain for the same reason (unopposed $\alpha$ stimulation).

Question 869: Telmisartan lowers blood pressure by:

A. Inhibiting formation of angiotensin I to angiotensin II
B. Inhibiting conversion of renin to angiotensin I
C. Blocking AT1 receptors (Correct Answer)
D. Interfering with degradation of bradykinin

Explanation: **Explanation:** **Telmisartan** belongs to the class of drugs known as **Angiotensin Receptor Blockers (ARBs)**. Its primary mechanism of action is the selective and competitive antagonism of the **Angiotensin II Type 1 (AT1) receptor**. By blocking these receptors, Telmisartan prevents the potent vasoconstriction, aldosterone secretion, and sympathetic activation normally induced by Angiotensin II, thereby lowering blood pressure. **Analysis of Options:** * **Option A (Inhibiting formation of Angiotensin II):** This describes the mechanism of **ACE Inhibitors** (e.g., Enalapril, Ramipril), which inhibit the Angiotensin-Converting Enzyme. * **Option B (Inhibiting conversion of Renin to Angiotensin I):** This describes the mechanism of **Direct Renin Inhibitors** (e.g., Aliskiren). * **Option D (Interfering with degradation of bradykinin):** This is a secondary effect of **ACE Inhibitors**. Because ARBs do not inhibit ACE, they do not increase bradykinin levels. This explains why ARBs are not typically associated with the dry cough or angioedema seen with ACE inhibitors. **High-Yield Clinical Pearls for NEET-PG:** * **Unique Property:** Telmisartan has the **longest half-life** (~24 hours) among ARBs, allowing for once-daily dosing. * **PPAR-γ Activity:** Unlike other ARBs, Telmisartan acts as a partial agonist of **PPAR-gamma**, which may provide additional metabolic benefits (improving insulin sensitivity). * **Uricosuric Effect:** While Telmisartan is standard, remember that **Losartan** is unique for its uricosuric property (useful in patients with gout). * **Contraindication:** Like ACE inhibitors, ARBs are strictly **contraindicated in pregnancy** (teratogenic) and in patients with bilateral renal artery stenosis.

Question 870: Cough is an adverse reaction with intake of which drug class?

A. Enalapril (Correct Answer)
B. Prazocin
C. Nifedipine
D. Thiazide

Explanation: ### Explanation **Correct Option: A (Enalapril)** Enalapril belongs to the **ACE Inhibitors (ACEIs)** class. The characteristic dry, hacking cough associated with ACEIs is primarily due to the accumulation of **Bradykinin** and **Substance P** in the respiratory tract. * **Mechanism:** ACE (Angiotensin-Converting Enzyme) is identical to Kininase II, the enzyme responsible for breaking down bradykinin. By inhibiting ACE, these drugs prevent bradykinin degradation. Elevated bradykinin levels sensitize sensory nerve endings in the lungs and stimulate the production of pro-inflammatory prostaglandins, leading to a persistent dry cough (occurring in 5–20% of patients). **Incorrect Options:** * **B. Prazocin:** An alpha-1 blocker used in hypertension and BPH. Its primary side effects are "first-dose" orthostatic hypotension and syncope, not cough. * **C. Nifedipine:** A Dihydropyridine Calcium Channel Blocker (CCB). Common side effects include peripheral edema, flushing, and headache due to vasodilation. * **D. Thiazide:** Diuretics that can cause hypokalemia, hyperuricemia, and hyperglycemia, but do not affect the kinin system or cause a cough. **High-Yield Clinical Pearls for NEET-PG:** * **Management:** If a patient develops an ACEI-induced cough, the drug should be stopped and switched to an **ARB (Angiotensin Receptor Blocker)** like Losartan, as ARBs do not interfere with bradykinin metabolism. * **Contraindications:** ACEIs are strictly **teratogenic** (cause fetal renal dysgenesis) and are contraindicated in **bilateral renal artery stenosis** (can precipitate acute renal failure). * **Other ACEI Side Effects:** Remember the mnemonic **CAPTOPRIL**: **C**ough, **A**ngioedema, **P**roteinuria/Potassium excess (Hyperkalemia), **T**aste changes, **O**rthostatic hypotension, **P**regnancy contraindication, **R**enal artery stenosis contraindication, **I**ndomethacin interaction, **L**eukopenia.

Practice by Chapter

Antihypertensive Agents

Practice Questions

Drugs for Heart Failure

Practice Questions

Antiarrhythmic Drugs

Practice Questions

Antianginal Agents

Practice Questions

Lipid-Lowering Drugs

Practice Questions

Anticoagulants and Antiplatelet Drugs

Practice Questions

Thrombolytic Agents

Practice Questions

Drugs Used in Pulmonary Hypertension

Practice Questions

Drugs Used in Shock

Practice Questions

Cardiovascular Effects of Non-Cardiovascular Drugs

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free